Christophe De Block - Concepedia

Author

Christophe De Block

Also Known As

C BLOCK, C Block, C De Block, C E De Block, C E M De Block, C. BLOCK, C. De Block, C. E. M. De Block, C. de Block, C.E. De Block

341

Publications

11.7K

Citations

H-Index

Concepts

All Affiliations

Antwerp University Hospital University of Antwerp KU Leuven Onze Lieve Vrouwziekenhuis Hospital Imelda Hospital

About

Christophe De Block is an author at Antwerp University Hospital specializing in medicine, diabetes, and metabolic syndrome.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	28	1.7K
2	Public Health	10	10	634
3	Health Sciences	7	7	601
4	Allergy	1	1	47
5	Biochemistry	1	1	50

Christophe De Block

Publications

6.2K

Citations

H-Index

Page 1

	Year	Citations
Insulin Needs after CD3-Antibody Therapy in New-Onset Type 1 Diabetes Bart Keymeulen, Evy Vandemeulebroucke, Anette G. Ziegler, New England Journal of Medicine	2005	1.1K
Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass Bart Keymeulen, Melanie Walter, Chantal Mathieu, Diabetologia ObesityMetabolic SyndromeDiabetes ManagementBody CompositionAutoimmune Disease	2010	310
Quality of Life and Glucose Control After 1 Year of Nationwide Reimbursement of Intermittently Scanned Continuous Glucose Monitoring in Adults Living With Type 1 Diabetes (FUTURE): A Prospective Observational Real-World Cohort Study Sara Charleer, Christophe De Block, Liesbeth Van Huffel, Diabetes Care	2019	252
Effect of Continuous Glucose Monitoring on Glycemic Control, Acute Admissions, and Quality of Life: A Real-World Study Sara Charleer, Chantal Mathieu, Frank Nobels, The Journal of Clinical Endocrinology & Metabolism	2018	185
Microbiome-derived ethanol in nonalcoholic fatty liver disease Abraham S. Meijnikman, Mark Davids, Hilde Herrema, Nature Medicine Metabolic Associated SteatohepatitisHepatologyMetabolic Associated Steatotic Liver DiseaseNonalcoholic Fatty Liver DiseaseLiver Physiology	2022	185
Allergic contact dermatitis caused by isobornyl acrylate in <scp>F</scp>reestyle® <scp>L</scp>ibre, a newly introduced glucose sensor Anne Herman, Olivier Aerts, Marie Baeck, Contact Dermatitis	2017	184
Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1) David Russell‐Jones, Bruce W. Bode, Christophe De Block, Diabetes Care	2017	176
Type 1 diabetes and autoimmune polyglandular syndrome: a clinical review. Ann Van Driessche, Vera Eenkhoorn, L. Van Gaal, PubMed	2009	173
Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial André Lacroix, Feng Gu, Wilson Gallardo, The Lancet Diabetes & Endocrinology Month Clinical TrialUrologyPituitary DiseaseAdrenal DiseaseEndocrinology	2017	163
Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial Matthias von Herrath, Stephen C. Bain, Bruce W. Bode, The Lancet Diabetes & Endocrinology Inflammationβ-Cell FunctionDiabetes ManagementAnti-interleukin-21 AntibodyDiabetes	2021	163

Page 1